The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis

Biochemical and Biophysical Research Communications

Volumn 394, Issue 3, 2010, Pages 673-678

  Kihara, Yasuyuki ^a   Yokomizo, Takehiko ^b,c   Kunita, Akiko ^d   Morishita, Yasuyuki ^d   Fukayama, Masashi ^d   Ishii, Satoshi ^a   Shimizu, Takao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Arachidonic acid cascade; Demyelination; Eicosanoid; Inflammation; Lipid mediator; MS

Indexed keywords

ACEBUTOLOL; GAMMA INTERFERON; INTERLEUKIN 6; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; LTB4R1 PROTEIN, MOUSE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL CORD; T LYMPHOCYTE; TH1 CELL; TH17 CELL; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL MOTION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; PATHOLOGY; TH2 CELL;

MUS;

AMINO ACID SEQUENCE; ANIMALS; CELL MOVEMENT; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, LEUKOTRIENE B4; SPINAL CORD; TH1 CELLS; TH2 CELLS;

EID: 77950521044     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.049     Document Type: Article

References (39)

1. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
2. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 49 (2009) 123-150
3. Yokomizo T., Izumi T., and Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch. Biochem. Biophys. 385 (2001) 231-241
4. Tager A.M., and Luster A.D. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukotrienes Essent. Fatty Acids 69 (2003) 123-134
5. Yokomizo T., Izumi T., Chang K., Takuwa Y., and Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 387 (1997) 620-624
6. Yokomizo T., Kato K., Terawaki K., Izumi T., and Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 192 (2000) 421-432
7. Hikiji H., Ishii S., Yokomizo T., Takato T., and Shimizu T. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc. Natl. Acad. Sci. USA 106 (2009) 21294-21299
8. Kim N., and Luster A.D. Regulation of immune cells by eicosanoid receptors. ScientificWorldJournal 7 (2007) 1307-1328
9. Haribabu B., Verghese M.W., Steeber D.A., Sellars D.D., Bock C.B., and Snyderman R. Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J. Exp. Med. 192 (2000) 433-438
10. Tager A.M., Dufour J.H., Goodarzi K., Bercury S.D., von Andrian U.H., and Luster A.D. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J. Exp. Med. 192 (2000) 439-446
11. Terawaki K., Yokomizo T., Nagase T., Toda A., Taniguchi M., Hashizume K., Yagi T., and Shimizu T. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J. Immunol. 175 (2005) 4217-4225
12. Medoff B.D., Tager A.M., Jackobek R., Means T.K., Wang L., and Luster A.D. Antibody-antigen interaction in the airway drives early granulocyte recruitment through BLT1. Am. J. Physiol. Lung Cell. Mol. Physiol. 290 (2006) L170-L178
13. Miyahara N., Miyahara S., Takeda K., and Gelfand E.W. Role of the LTB4/BLT1 pathway in allergen-induced airway hyperresponsiveness and inflammation. Allergol. Int. 55 (2006) 91-97
14. Tager A.M., Bromley S.K., Medoff B.D., Islam S.A., Bercury S.D., Friedrich E.B., Carafone A.D., Gerszten R.E., and Luster A.D. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4 (2003) 982-990
15. Kim N.D., Chou R.C., Seung E., Tager A.M., and Luster A.D. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J. Exp. Med. 203 (2006) 829-835
16. McFarland H.F., and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8 (2007) 913-919
17. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., Uccelli A., Lanzavecchia A., Engelhardt B., and Sallusto F. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10 (2009) 514-523
18. Bettelli E., Korn T., Oukka M., and Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 453 (2008) 1051-1057
19. Bettelli E., Oukka M., and Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8 (2007) 345-350
20. Kroenke M.A., Carlson T.J., Andjelkovic A.V., and Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205 (2008) 1535-1541
21. Huppert J., Closhen D., Croxford A., White R., Kulig P., Pietrowski E., Bechmann I., Becher B., Luhmann H.J., Waisman A., and Kuhlmann C.R. Cellular mechanisms of IL-17-induced blood-brain barrier disruption. FASEB J. (2009) 10.1096/fj.09-141978
22. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., and Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13 (2007) 1173-1175
23. Kalyvas A., and David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41 (2004) 323-335
24. Marusic S., Leach M.W., Pelker J.W., Azoitei M.L., Uozumi N., Cui J., Shen M.W., DeClercq C.M., Miyashiro J.S., Carito B.A., Thakker P., Simmons D.L., Leonard J.P., Shimizu T., and Clark J.D. Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J. Exp. Med. 202 (2005) 841-851
25. Marusic S., Thakker P., Pelker J.W., Stedman N.L., Lee K.L., McKew J.C., Han L., Xu X., Wolf S.F., Borey A.J., Cui J., Shen M.W., Donahue F., Hassan-Zahraee M., Leach M.W., Shimizu T., and Clark J.D. Blockade of cytosolic phospholipase A(2)alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J. Neuroimmunol. 204 (2008) 29-37
26. Kihara Y., Matsushita T., Kita Y., Uematsu S., Akira S., Kira J., Ishii S., and Shimizu T. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl. Acad. Sci. USA 106 (2009) 21807-21812
27. Kihara Y., Ishii S., Kita Y., Toda A., Shimada A., and Shimizu T. Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor. J. Exp. Med. 202 (2005) 853-863
28. Kihara Y., Yanagida K., Masago K., Kita Y., Hishikawa D., Shindou H., Ishii S., and Shimizu T. Platelet-activating factor production in the spinal cord of experimental allergic encephalomyelitis mice via the group IVA cytosolic phospholipase A2-Lyso-PAFAT axis. J. Immunol. 181 (2008) 5008-5014
29. Iizuka Y., Yokomizo T., Terawaki K., Komine M., Tamaki K., and Shimizu T. Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J. Biol. Chem. 280 (2005) 24816-24823
30. Emerson M.R., and LeVine S.M. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res. 1021 (2004) 140-145
31. Gladue R.P., Carroll L.A., Milici A.J., Scampoli D.N., Stukenbrok H.A., Pettipher E.R., Salter E.D., Contillo L., and Showell H.J. Inhibition of leukotriene B4-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. J. Exp. Med. 183 (1996) 1893-1898
32. Okuno T., Iizuka Y., Okazaki H., Yokomizo T., Taguchi R., and Shimizu T. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J. Exp. Med. 205 (2008) 759-766
33. McColl S.R., Staykova M.A., Wozniak A., Fordham S., Bruce J., and Willenborg D.O. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 161 (1998) 6421-6426
34. F. Wu, W. Cao, Y. Yang, A. Liu, Extensive infiltration of neutrophils in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 mice, Histochem. Cell Biol., 2010, doi:10.1007/s00418-009-0673-2.
35. Hendriks J.J., Teunissen C.E., de Vries H.E., and Dijkstra C.D. Macrophages and neurodegeneration. Brain Res. Brain Res. Rev. 48 (2005) 185-195
36. A. Toda, K. Terawaki, S. Yamazaki, K. Saeki, T. Shimizu, T. Yokomizo, Attenuated Th1 induction by dendritic cells from mice deficient in the leukotriene B4 receptor 1, Biochimie, 2009, doi:10.1016/j.biochi.2009.12.002.
37. Neu I., Mallinger J., Wildfeuer A., and Mehlber L. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. Acta Neurol. Scand. 86 (1992) 586-587
38. Neu I.S., Metzger G., Zschocke J., Zelezny R., and Mayatepek E. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol. Scand. 105 (2002) 63-66
39. Chen H., Qin J., Wei P., Zhang J., Li Q., Fu L., Li S., Ma C., and Cong B. Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells. Prostaglandins Leukotrienes Essent. Fatty Acids 80 (2009) 195-200